Stocks showed a split reaction Thursday as the Dow and S&P 500 rose with buyers favoring non-tech sectors, while the Nasdaq struggled due to ongoing pressure on AI and memory-chip stocks. The Producer Price Index (PPI) came in hotter than expected, reinforcing inflation concerns after a strong Consumer Price Index (CPI) report, keeping the possibility of another Federal Reserve rate hike alive. Despite this, Treasury yields fell as bond buyers stepped in, pushing the 10-year yield down to around 5.06%, while gold prices rose over 1% supported by weaker dollar and lower yields. The market remains cautious, with tech stocks under pressure and defensive sectors like Walmart and Merck gaining, signaling a preference for safer investments amid inflation worries and Fed policy uncertainty.
As of Oct 15, 2026 23:41 WIB, Walmart shares on Pluang gained 2.33%, trading at USD 118.87, closer to its 52-week low of USD 100.61 than its high of USD 134.20, reflecting cautious buying in defensive sectors amid inflation concerns. Meanwhile, Merck rose 1.54% to USD 149.63, positioned near its 52-week high of USD 156.43, showing stronger investor interest in healthcare compared to consumer staples during this period of market uncertainty.
Walmart's stock rose 3% following a Deutsche Bank upgrade to Buy, driven by strong pricing power and accelerating market share in groceries and digital segments. This gain contrasts with a broader retail sector decline, highlighting Walmart's appeal ...
Costco's stock trades at a high valuation of about 46 times trailing earnings, yet investors continue buying due to strong membership loyalty, steady traffic growth, and consistent earnings beats. The company reported a strong fiscal Q4 with revenue ...
Walmart's stock gained 3% following a hotter-than-expected inflation report that shifted investor interest toward retailers selling everyday necessities. While Walmart leads with a 4% gain year-to-date, Costco and Target also rose but at slower rates...
Walmart announced it will cover over 250 prescriptions at no cost to employees starting in 2027, including insulin, inhalers, and diabetes drugs Ozempic and Mounjaro for Type 2 diabetes after prior authorization. This move aims to attract and retain ...
